Review of Diagnostic and Therapeutic Implications of EGFR Exon 20 Insertions in Metastatic Non-Small Cell Lung Cancer
Course | English | 2023 | 90 Min
Image For Activity Cover
Credit Offered
1.5 ACCME Credits
1.5 Certificate of Attendance Credits

Precision Oncology aims to use cancer treatments that are targeted to individual patients on the basis of genetic, biomarker, phenotypic, or psychosocial characteristics. Technical advances in genome sequencing and the implementation of next-generation sequencing (NGS) in clinical oncology is paving the way for this individualized patient therapy based on molecular profiles. In this context, physicians must be aware of the clinical evidence behind the NGS tests available, in order to use them in the right moment.

This review will focus on the use of NSG testing for mutations in the epidermal growth factor receptor (EGFR) gene which is the most common targetable genomic drivers in non-small cell lung cancer (NSCLC).

Sponsored by the International Association for the Study of Lung Cancer (IASLC) and Johnson & Johnson Innovative Medicine (Janssen).

Live Activity Date: November 28, 2023
Enduring Activity Launch Date: January 10, 2024
Enduring Activity Expiration Date: January 9, 2025

This CME activities are designed for multidisciplinary teams of medical oncologists, pathologists, histologists, clinical radiation oncologists, pulmonologists, translational scientists, nurses, nurse practitioners, scientists, specialty pharmacists and physician assistants globally.

Upon completion of this activity, the participants should be able to: 
  • Summarize the biological background of EGFR mutations especially EGFR exon 20 insertions.
  • Review the prognostic implications and various treatment options for patients with EGFR exon20 insertion mutations.
  • Discuss the current guideline- recommended testing / detection methods for EGFR exon 20 insertions including NGS-based technology.

This activity is supported by an independent educational grant from Johnson & Johnson Innovative Medicine (Janssen).

  • Joshua K. Sabari, MD, Assistant Professor of Medicine, Thoracic Medical Oncology and Phase I, NYU Langone Health Perlmutter Cancer Center, USA 
  • Pilar Garrido, MD, PhD, Professor, Head of Medical Department, Ramón y Cajal Hospital, Spain 
  • Deepali Jain, MD, FIAC, FRCPath, Professor, Department of Pathology, All India Institute of Medical Sciences, India 
  • Natasha B. Leighl, MD MMSc FRCPC FASCO, Lung Site Lead, Medical Oncology, Princess Margaret Cancer Centre, OSI Pharmaceuticals Foundation Chair, PMC Foundation, Professor, Department of Medicine, University of Toronto, Adjunct Professor, IHPME, Dalla Lana School of Public Health, Canada 
The following planners, speakers, reviewers, or staff have relevant financial relationships to disclose: 

Full Legal Name Commercial Interest Role Level of Participation in the Activity
Pilar Garrido AbbVie, Amgen, AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Daiichi Sankyo, GSK, Janssen, Lilly, MSD, Novartis, Pfizer, Roche, Sanofi, Takeda Advisor Speaker
  Medscape and Touch Medical Direct Funding  
  Amgen, AstraZeneca, Blueprint, Boehringer Ingelheim, Daiichi Sankyo, GSK, Janssen, IO Biotech, Lilly, MSD, Roche, Takeda Research Funding (Paid to Institution)  
Natasha Leighl AstraZeneca, Janssen, Sanofi, MSD, Eisai Research Funding Speaker
  Janssen, Sanofi, MSD Travel Funding  
  Beigene Advisory Board  
  Takeda, BMS Consultant  
Joshua Sabari AstraZeneca, AbbVie, Gilead, Genentech, Janssen, Jazz, Mirati, Navire, Pfizer, Regeneron, Sanofi Genzyme, Takeda Consultant Moderator

"I have at present or have had within the last 24 months, a financial relationship with one or more ineligible companies."

These relationships with ineligible companies have been mitigated by the International Association for the Stufy of Lung Cancer (IASLC). 

All other presenters, planners, editors, or staff report no relationshops to disclose:

"I do not have at present nor have had within the last 24 months, any financial relationships with ineligible companies."

Accreditation Statement: 
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME). The International Association for the Study of Lung Cancer is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statements:

The International Association for the Study of Lung Cancer designates the enduring format for this educational activity for a maximum of 1.50 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Nurse Practitioners and Registered Nurses
For the purpose of recertification, the American Nurses Credentialing Center accepts AMA PRA Category 1 Credit™ issued by organizations accredited by the ACCME (Accreditation Council for Continuing Medical Education).

Physician Assistants
The National Commission on Certification of Physician Assistants (NCCPA) states that the AMA PRA Category 1 Credits™ are acceptable for continuing medical education requirements for recertification.

International CPD Credit Reciprocity Agreements

The Royal College will recognize the number of participation hours as MOC Program Section 1 accredited group learning credits for group learning activities developed by Accreditation Council for Continuing Medical Education (ACCME)-accredited physician organizations (university, academy, specialty society, hospital department etc.) that are held within and outside of Canada. Agreement dates: November 1, 2019 to December 31, 2025.

European Union
The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 credit™ into European CME credit (ECMEC) should contact the UEMS (

The American Medical Association (AMA) and the Department of Healthcare Professions–Accreditation Section (DHP-AS), Ministry of Public Health–Qatar have renewed their CME agreement under which select activities approved for AMA PRA Category 1 Credit™ are eligible for conversion of the hours of participation to Department of Healthcare Professions Continuing Professional Development (DHP-CPD) credit. This agreement is in place through Dec. 31, 2026.
The information presented is that of the contributing faculty and does not necessarily represent the views of the International Association for the Study of Lung Cancer and/or any named commercial entity providing financial support. Specific therapies discussed may not be approved and/or specified for use as indicated by the faculty presenters. Therefore, before prescribing any medication, please review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse effects.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; participants should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:
  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out, if applicable.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test.
  4. Complete the activity evaluation to provide feedback for future programming and receive credit.
You may now view or print the certificate from your CME/CE Transcript. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Transcript and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Transcript.

*The credit that you receive is based on your membership profile.
If you need assistance with this activity, please email:
Powered By